Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous…
| Periodo | 2026-05 | 2026-04 | 2026-02 | 2025-11 |
|---|---|---|---|---|
| Real | $0.27 | — | $-0.55 | $-1.00 |
| Estimado | $-0.08 | $0.43 | $-0.24 | $-0.12 |
| Sorpresa | +437.5% | — | -129.2% | -733.3% |
| Métrica | ASND | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 86.8% | 57.4% | +29.4% |
| Operating Margin | -18.9% | -34.4% | +15.5% |
| Net Margin | -31.7% | -32.5% | +0.8% |
| FCF Margin | — | -12.6% | — |
| ROE | — | -39.2% | — |
| ROA | -17.5% | -30.9% | +13.4% |
| Current Ratio | 1.04 | 2.73 | -1.69 |
| Debt / Equity | -2.37 | 0.28 | -2.65 |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -17.5% | — |
| ✓Flujo de caja operativo positivo | €54M | −€306M |
| ✓Rentabilidad sobre activos al alza | -17.5% | -32.1% |
| ✓Caja operativa/activos supera al ROA | 4.1% | ROA -17.5% |
| ✓Menos deuda a largo plazo | 29.6% | 31.0% |
| ✗Mejor liquidez (ratio corriente) | 1.04 | 1.17 |
| ✗Sin aumentar el nº de acciones | 61M | 58M |
| ✗Margen bruto al alza | 86.8% | 87.8% |
| ✓Rotación de activos al alza | 0.55 | 0.31 |
| Calidad del negocio | FY25 |
|---|---|
| ✗ROCE > 10 % | -58.4% |
| ✓Ventas > 5 %/año (3 años) | 141.4% |
| ✓Deuda neta/EBITDA < 3x | -1.0x |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 42.2% |
Ascendis Pharma A/S cotiza a 225.25 USD y tiene una capitalización bursátil de $14.8B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud